Chronic obstructive pulmonary disease (COPD) is the third most common cause of death in
the USA. In 2010, the cost of COPD in the USA was projected to be approximately US …

Background and Objectives Chronic obstructive pulmonary disease (COPD) affects over 250
million people globally, carrying a notable economic burden. This systematic literature …

The costs of chronic obstructive pulmonary disease (COPD) pose a major economic burden
to the United States. Studies evaluating COPD costs have generated widely variable …

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease
responsible for a large human and economic burden around the world. Cigarette smoking is …

Chronic obstructive pulmonary disease (COPD) is a progressive disorder of airflow limitation
that is not fully reversible, with disabling symptoms including chronic cough and dyspnoea …

Chronic obstructive pulmonary disease (COPD) is a multicomponent disease with
inflammation at its core, and a major cause of morbidity and mortality. It represents a …

RATIONALE: Although the economic burden of COPD has gained attention in recent years,
data on the costs of COPD among US Medicare beneficiaries are lacking. METHODS: This …

In today9s cost-conscious environment, understanding the economic implications
associated with disease processes and their treatments is as important as understanding …

Background: Lack of information about economic burden of COPD is a major cause of lack
of attention to this chronic condition from governments and policymakers. Objective: To find …

Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity.
Relatively few pharmacoeconomic studies have been conducted on this disease. This article …